NGM Bio Announces Initiation of Phase 1/1b Clinical Study of NGM438 for the Treatment of Patients with Advanced Solid Tumors

NGM Biopharmaceuticals, Inc. announced it has initiated a Phase I/Ib clinical study of NGM438 for the treatment of patients with advanced solid tumors.